TMZ

DRUG15 trials

Sponsors

Boehringer Ingelheim, King Faisal Specialist Hospital & Research Center, Eisai Inc., Peking Union Medical College Hospital, Novartis Pharmaceuticals

Conditions

Brain CancerBrain MetastasisBrain and Central Nervous System TumorsBreast CancerColorectal CancerGlioblastomaGlioblastoma (GBM)Glioblastoma Multiforme

Early Phase 1

Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme

The Second Hospital of Hebei Medical UniversityGlioblastoma Multiforme

Start: 2022-10-31End: 2024-07-31Target: 10Updated: 2022-10-21

Phase 1

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

CompletedNCT02903069

CelgeneGlioblastoma, Malignant Glioma

Start: 2016-08-17End: 2021-01-25Updated: 2021-04-19

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

CompletedNCT03150862

BeiGene USA, Inc.Brain and Central Nervous System Tumors

Start: 2017-07-24End: 2021-03-17Updated: 2025-02-04

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

TerminatedNCT03190967

National Cancer Institute (NCI)Brain Cancer, Brain Metastasis, Breast Cancer

Start: 2018-04-18End: 2023-06-13Updated: 2023-10-11

A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients

CompletedNCT03867123

Laminar PharmaceuticalsGlioblastoma (GBM)

Start: 2018-12-04End: 2020-07-01Updated: 2023-02-21

Phase 2

BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

CompletedNCT00727506

Boehringer IngelheimGlioma

Start: 2008-07-14End: 2016-05-25Updated: 2017-08-15

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

TerminatedNCT01605162

Eisai Inc.Unresectable Stage III Melanoma, Wild Type BRAF Stage IV Melanoma

Start: 2012-05-31End: 2014-02-28Updated: 2016-07-28

Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas

Peking Union Medical College HospitalMalignant Gliomas

Start: 2012-08-31Target: 120Updated: 2012-08-22

A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

CompletedNCT01708174

Novartis PharmaceuticalsMedulloblastoma

Start: 2013-05-06End: 2016-10-05Updated: 2017-08-11

A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases

Sun Yat-sen UniversityBrain Metastasis, Radiation Therapy Complication

Start: 2016-07-31End: 2017-12-31Target: 256Updated: 2016-07-14

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

WithdrawnNCT03879811

Memorial Sloan Kettering Cancer CenterColorectal Cancer

Start: 2019-03-13End: 2021-03-31Updated: 2025-05-15

LAM561 With RT and TMZ for Adults With Glioblastoma

Active, not recruitingNCT04250922

Laminar PharmaceuticalsGlioblastoma Multiforme, Primary Glioblastoma

Start: 2019-12-01End: 2026-11-30Updated: 2025-11-20

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Active, not recruitingNCT04817254

National Cancer Institute (NCI)Glioblastoma, Gliosarcoma, Malignant Glioma

Start: 2021-12-08End: 2027-12-31Updated: 2026-03-18

Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

RecruitingNCT06816927

Duke UniversityNewly Diagnosed Glioblastoma

Start: 2025-11-28End: 2031-06-01Target: 92Updated: 2026-01-09

Phase 3

Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma

CompletedNCT01364064

King Faisal Specialist Hospital & Research CenterGlioblastoma

Start: 2007-01-31End: 2008-06-30Updated: 2016-02-25

Related Papers

Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma

Current Oncology2025-09-27

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.

2025-02-2731 citations

Abstract 4729: Incorporation of the antitumor compound 2OHOA and its metabolite into cell membranes

Cancer Research2024-03-221 citations

A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.

2023-07-2411 citations

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

British Journal of Cancer2021-11-1811 citations

Pamiparib dose escalation in Chinese patients with non‐mucinous high‐grade ovarian cancer or advanced triple‐negative breast cancer

Cancer Medicine2020-10-3119 citations

Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

Neoplasia2020-07-0895 citations

Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-positive breast cancer brain metastases following stereotactic radiosurgery.

Journal of Clinical Oncology2020-05-20

Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Future Oncology2020-04-0933 citations

Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors

Neuro-Oncology Advances2020-01-0117 citations

ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE

Neuro-Oncology2019-11-0116 citations

Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).

Journal of Clinical Oncology2019-05-2010 citations

ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)

Neuro-Oncology2018-11-017 citations

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

Neuro-Oncology2018-11-011 citations

ATRT-18. VALIDATION OF PROTEASOME INHIBITION AS A THERAPEUTIC TARGET IN ATYPICAL TERATOID/RHABDOID TUMORS

Neuro-Oncology2018-06-01

A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results.

Journal of Clinical Oncology2018-05-206 citations

ACTR-45. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM)

Neuro-Oncology2017-11-01